,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2012-11-13 02:30:00,We reiterate our Neutral recommendation on St. Jude Medical ( STJ ).,0.04435713589191437,0.034272972494363785,0.9213698506355286,neutral,0.010084163397550583
1,2012-11-13 02:30:00,St. Jude reported third quarter 2012 adjusted earnings per share of 83 cents (up 6.4% year-over-year).,0.951233983039856,0.021379761397838593,0.027386216446757317,positive,0.9298542141914368
2,2012-11-13 02:30:00,The results also beat the Zacks Consensus Estimate by 2 cents.,0.9387313723564148,0.03244755417108536,0.028820984065532684,positive,0.9062837958335876
3,2012-11-13 02:30:00,"However, profits dropped 22.5% to $176 million (or 56 cents a share) on account of weak revenue generation and a contraction in operating margin.",0.01704862341284752,0.9730708003044128,0.009880522266030312,negative,-0.9560222029685974
4,2012-11-13 02:30:00,"Reported net revenues of $1,326 million were down 4% year over year and also missed the Zacks Consensus Estimate of $1,342 million.",0.017569931223988533,0.9728333950042725,0.009596655145287514,negative,-0.9552634358406067
5,2012-11-13 02:30:00,Net sales grew less than 1% on constant currency basis.,0.031365424394607544,0.7436981797218323,0.22493642568588257,negative,-0.7123327255249023
6,2012-11-13 02:30:00,"All segments reported disappointing results, especially Cardiac Rhythm Management (CRM) and Cardiovascular units, except the Atrial Fibrillation (AF) business.",0.01825803332030773,0.952568769454956,0.029173199087381363,negative,-0.9343107342720032
7,2012-11-13 02:30:00,"With a market-cap of $11.70 billion, St. Jude is a leading provider of medical devices with a number of growth drivers, which are expected to boost sales over the long term.",0.9465281963348389,0.016110463067889214,0.037361353635787964,positive,0.9304177165031433
8,2012-11-13 02:30:00,The company is well positioned to savor incremental opportunities on the back of a strong product pipeline.,0.9156615734100342,0.013501184992492199,0.07083722949028015,positive,0.9021604061126709
9,2012-11-13 02:30:00,The AF market has become one of the best growth opportunities in the MedTech space.,0.8700027465820312,0.013398735783994198,0.11659855395555496,positive,0.8566040396690369
10,2012-11-13 02:30:00,"With a market size of roughly $2.4 billion, St. Jude is growing at a double-digit rate in this market, driven by higher sales of ablation catheters, capital equipment and disposable products.",0.9306214451789856,0.015636948868632317,0.053741637617349625,positive,0.9149845242500305
11,2012-11-13 02:30:00,"Moreover, the company identified seven major growth drivers in the CV business alone, which are anticipated to boost sales to over $2 billion annually after their maturity.",0.9468410015106201,0.016513342037796974,0.03664560988545418,positive,0.9303276538848877
12,2012-11-13 02:30:00,St. Jude's 2012 business realignment plan is focused on improving the company's operating margin in the face of a tough macroeconomic environment.,0.9414156079292297,0.015660546720027924,0.042923856526613235,positive,0.9257550835609436
13,2012-11-13 02:30:00,The company plans to utilize this savings to fund its portfolio of new growth drivers and maintain its industry leading position.,0.9228346943855286,0.01481073722243309,0.062354594469070435,positive,0.9080239534378052
14,2012-11-13 02:30:00,This measure was necessary to hedge against the upcoming MedTech tax from 2013 and generate double-digit bottom-line growth.,0.9004403948783875,0.015260317362844944,0.08429933339357376,positive,0.8851800560951233
15,2012-11-13 02:30:00,"While a host of new growth drivers (including new products, cost saving measures and share buyback programs) are expected to boost results in 2013 and beyond, we remain cautious about increased competition, a weakening Euro, the soft CRM business and the overall tough macroeconomic conditions.",0.851414680480957,0.06220145523548126,0.08638390153646469,positive,0.789213240146637
16,2012-11-13 02:30:00,The company's downward revision of its core CRM sales is a significant cause of concern.,0.0228659026324749,0.9501006603240967,0.027033448219299316,negative,-0.9272347688674927
17,2012-11-13 02:30:00,"The prevailing macroeconomic factors, realignment expenses, pricing pressure, austerity measures and the impact of the health care reforms are weighing down on the CRM market moving ahead.",0.03464724123477936,0.7426896095275879,0.22266320884227753,negative,-0.7080423831939697
18,2012-11-13 02:30:00,"Further, the implantable cardioverter defibrillator systems (ICD) business continues to be plagued by reliability issues concerning the high-voltage lead product lines.",0.02299836091697216,0.9476425647735596,0.02935909479856491,negative,-0.9246442317962646
19,2012-11-13 02:30:00,A choppy CRM space continues to overhang on St. Jude and its peers Medtronic ( MDT ) and Boston Scientific ( BSX ).,0.022399403154850006,0.9315192103385925,0.04608142748475075,negative,-0.9091197848320007
20,2012-11-13 02:30:00,To read this article on Zacks.com click here.,0.01796119473874569,0.0192450862377882,0.9627937078475952,neutral,-0.001283891499042511
21,2012-11-13 02:30:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
